Popular on Amzeal
- Terrorist? Thats What This Entrepreneur Grew Up Being Called, That Didn't Stop Him
- What Donald Trump Doesn't Seem To Know About Women
- Women to Watch Summit Draws Record Numbers, Celebrating and Empowering Women in STEM
- Hill Helicopters Adopts GL Studio for Avionics Suite Development
- Job Search Trends Highlight Shift Toward Sustainability and Automation in Engineering and Manufacturing Sectors
- IntellaTriage Names Olivia Gaffney, RN as 2022 Nurse of the Year Honoree
- NOYNIM Relaunches Webpage on IT Services for the Manufacturing Industry
- Actionstep Academy Provides Added Training Value to Platform Customers
- Realty Connect Expands and Enlists Happy Grasshopper to Power Agent Communication
- Catapult Lakeland to host the VC Fast Pitch on June 8th
Similar on Amzeal
- Calvetta Phair, CEO of America's Workforce Solution, LLC, accepted into the Nasdaq Entrepreneurial Center, 'Milestone Circles' Program
- Australian Battery Recycling Technology Startup Advances Its Innovative Battery Metals Recovery Process
- Trump Bus Tour sponsored by Legacy PAC will roll into the Georgia GOP State convention June 9th and 10th Columbus Georgia
- Pettit Kohn Welcomes Esteemed Attorney John E. Drazkowski to the Arizona Team
- Golden Ticket Productions Launches New Website
- Orbex Launches New ZERO Spread Trading Account with $1 Commission per Side
- Registration is Now Open for the 2023 CGI Integrated Care Conference
- Latino Leaders Network to Honor Mayor Kate Gallego of Phoenix with the Antonio Villaraigosa Leadership Award at the 38th Tribute to Mayors
- Levinger-Regens Analytics Reveals New Energy Outlook
- Sip Social Co. Mobile Bar Trucks Showcased At BC Home + Garden Show Presents New Opportunities To Partner With Marketplace Events
Huma named for its successful and innovative approach to clinical trials in new UK government review USA - English USA - English
Amzeal News/10526184
- Huma's innovative approach to medical research cited in Lord James O'Shaughnessy's review for clinical trials improvement in the UK
- The review is part of a new widespread policy approach to ignite the UK's life sciences sector
- Innovating clinical trials using digital technologies such as Huma's platforms can make them more accessible, more diverse, faster to recruit and retain patients
NEW YORK and LONDON, May 25, 2023 /PRNewswire/ -- Huma Therapeutics ("Huma"), a leading global digital health company, is named today as an exemplar of innovation in medical research in an independent review led by former Health Minister, Lord James O'Shaughnessy entitled Commercial clinical trials in the UK.
The review was commissioned by the UK government to make recommendations to improve the clinical trials landscape in the UK. It proposes a range of 'significant actions' to bend the performance curve of trials dramatically, stating: 'The partnership between 2 very different UK life science success stories – AstraZeneca and Huma – shows the potential of the UK in this field'. The review includes a short case study of our joint work1.
The review proposes that the government doubles the numbers of people taking part in commercial clinical trials in the next two years, and doubles it again by 2027. One of its 27 recommendations is the support and promotion of decentralised clinical trials, which are enabled by digital technology. It calls on stakeholders to develop guidance for decentralised and innovative trials by the end of 2023 to keep pace internationally.
Decentralised clinical trials
An estimated 80% of clinical trials do not meet initial patient enrollment goals and timelines2. Decentralised trials can, says the review, increase public involvement in research and new therapies. Data can be collected from the comfort of participants' homes without disrupting their lives, reducing or eliminating the need to travel to clinical trial sites. Retention and adherence to trial protocols through an improved experience can lower the overall cost of research. Decentralised trials also hold the promise of increasing diversity so that new medicines benefit people from all ethnicities and backgrounds.
More on Amzeal News
- Calvetta Phair, CEO of America's Workforce Solution, LLC, accepted into the Nasdaq Entrepreneurial Center, 'Milestone Circles' Program
- Australian Battery Recycling Technology Startup Advances Its Innovative Battery Metals Recovery Process
- Trump Bus Tour sponsored by Legacy PAC will roll into the Georgia GOP State convention June 9th and 10th Columbus Georgia
- Miss Beloit Organizes Event to Foster STEM Careers for Underserved Communities through Video Games
- Pettit Kohn Welcomes Esteemed Attorney John E. Drazkowski to the Arizona Team
Dan Vahdat, Founder & CEO of Huma, said: "As a UK-headquartered company we really want to play our role in supercharging bodies such as the NHS and helping the UK re-establish its leadership position in clinical research. We have the innovative platform and clinical trials expertise to do so: our technology has supported some of the world's largest clinical trials from Covid19 to the Our Future Health study aiming to carry out research on 5 million participants. We join Lord O'Shaughnessy's call for all stakeholders to come together with both a renewed ambition and innovative mindset to bend the performance curve of clinical trials in the UK."
Huma's digital technology platforms support decentralised trials through an easy to configure, end-to-end solution, without hard coding, which allows rapid setup for clinical study requirements. This features pre-built modules including eConsent, ePRO and eCOA that can be adapted to protocols enabling quick setup of therapeutic study requirements.
References:
- Commercial clinical trials in the UK: the Lord O'Shaughnessy review. Case study: AstraZeneca and Huma partnership
In March 2022, AstraZeneca, a global, science-led biopharmaceutical company headquartered in the UK, took a step towards harnessing this technology-driven, decentralised clinical trial opportunity through its partnership with Huma Therapeutics, a leading global digital health company also headquartered in the UK.
Huma's technology platform is founded on the first and only disease-agnostic software as a medical device (SaMD) to hold EU Medical Device Regulations (MDR) class IIb certification status. Its adaptations are used on a global scale by more than 1.8 million patients across around 3,000 hospitals and clinics and by more than 650,000 participants across research. Through Huma's primary care division, iPLATO Healthcare, whose digital service is used by 31 million people across the UK, digital technology is also driving recruitment into the UK's largest research programme, Our Future Health, through text messages and push notifications to invite people to join this incredible research programme.
More on Amzeal News- "Sensory VoiceHub 2.0: Rapid Custom Voice UI Dev & Prototyping with Generative AI"
- Vantiva receives EcoVadis Platinum Award & ranks in Top 2% of responsible companies by S&P Global
- INshed Now Offers Nationwide Shipping of Fully-Assembled, Eco-Friendly Backyard Offices
- SatPhoneStore Prepares for Hurricane Season, Encourages Satellite Communications for Reliable Connectivity
- Entrinsik Appoints Madhavi W. Chandra as Chief Product Officer
Partnering with Huma enables AstraZeneca to conduct clinical trials in an entirely new way. For example, a global decentralised study of AstraZeneca's COVID-19 vaccine was designed to allow participants to report data on mobile phones across multiple continents, without ever visiting a trial site. In Germany, Huma and AstraZeneca worked together on a real-world evidence study to identify patients at risk of developing chronic kidney disease, resulting in the potential to recruit 7,000 patients in a single month.
These are powerful examples of a global pharma leader partnering with a British technology company to show the potential of digital-first care and research.
By combining digital technology with investigational research, AstraZeneca and Huma believe that this innovative approach will deliver marked improvements in the clinical trials space, ultimately resulting in the faster delivery of new and better medicines to patients in the UK and worldwide. - Johnson, O. (2015). An evidence-based approach to conducting clinical trial feasibility assessments. Clinical investigation, 5, 491-499.
About Huma
Huma Therapeutics is a global digital health technology company that advances digital-first care delivery and research to help people live longer, fuller lives.
Huma's award-winning modular platforms are used by more than 3,000 hospitals and clinics, with 1.8+ million active users in healthcare and 650,000+ participants across research. Huma's regulated Software as a Medical Device is the only platform to hold EU MDR Class IIb regulatory status. It powers:
- Digital first care for health systems
- companion apps to support patients through treatment and drug therapies
- virtual clinical trials to accelerate research
Please visit www.huma.com and follow us on LinkedIn at Huma
Media contact:
Karen Birmingham PhD
Head of PR & Communications, Huma
[email protected]
+44 (0) 7866 609314
Logo: https://mma.prnewswire.com/media/1427908/Huma_Logo.jpg
SOURCE HUMA Therapeutics
Filed Under: Business
0 Comments
Latest on Amzeal News
- Latino Leaders Network to Honor Mayor Kate Gallego of Phoenix with the Antonio Villaraigosa Leadership Award at the 38th Tribute to Mayors
- MyTEPI Agrees to Partner with John Abrams, Ph.D. and Jean Talleyrand, M.D
- Century Fasteners Corp. – Robert D. Botticelli, Hired
- Levinger-Regens Analytics Reveals New Energy Outlook
- UVify Unveils the Groundbreaking SLAMDAQ
- Dancing Numbers Unveils Google Sheets QuickBooks Integration, Streamlining Data Import, Export, and Deletion
- Truiem Sponsoring CxOutsourcers Mindshare Event
- ASKA performs ground and systems testing, on-street driving tests of ASKA™ A5 drive and fly eVTOL
- ReadyCommunities Partnership of CCROA Announces National Service Awardees Who Helped Save Passengers from the Derailed Train Near Rural Mendon
- UVify, a leader in the field of swarm and autonomous drones to participate in ICRA 2023
- Federico Welsh, new Chief Human Capital Officer at NEORIS
- Bitcoin Mining Capacity Reaches 350 Exahashes/second
- Up To 70% Off! Alibonnie Graduation Season Wig Surprise Discount
- Gemini IT Producer Software is Reshaping the Filmmaking Industry
- Tech Pioneer Aims to Save the Environment with New Work-From-Anywhere Eco Venture
- SEM Link wins grant to narrow gaps in health, wealth, and opportunity for Atlanta youth
- 130k+ Patients' Social Security Numbers Leaked in UHS of Delaware Data Breach
- Sip Social Co. Mobile Bar Trucks Showcased At BC Home + Garden Show Presents New Opportunities To Partner With Marketplace Events
- Ohio Pacing Stallion Catch The Fire Is Heading To Australia
- IntellaTriage Names Olivia Gaffney, RN as 2022 Nurse of the Year Honoree